Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1127480 | 0.81 | — | — | |
| SCHEMBL7429001 | 0.79 | CCR3 (0.41) | PPM1BPTPN1PPP1CCTSHRCCR3 | |
| SCHEMBL9787827 | 0.76 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL31429546 | 0.76 | — | — | |
| SCHEMBL22700052 | 0.76 | TSHR (0.44) | TSHR | |
| SCHEMBL9744206 | 0.74 | CCR3 (0.36) | CCR3ALDH1A1 | |
| SCHEMBL11338964 | 0.72 | MIF (0.38) | TSHRALDH1A1MEN1GAAHPGD | |
| SCHEMBL14765393 | 0.72 | — | — | |
| SCHEMBL31429466 | 0.71 | KDM4E (0.45) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL11063859 | 0.69 | PPM1B (0.38) | PPM1BPTPN1PPP1CCTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658657-B2 | — | — | 2014-02-25 | — | — | US | disclosed |
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-0968194-B1 | ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2004-05-26 | — | — | EP | disclosed |
| EP-0964860-B1 | ATROPISOMERS OF 3-HETEROARYL-4(3H)-QUINAZOLINONES FOR THE TREATMENT OF NEURODEGENERATIVE AND CNS-TRAUMA RELATED CONDITIONS | PFIZER PROD INC (US) | 2004-04-21 | — | — | EP | disclosed |
| US-6465462-B1 | COGNITION ENHANCEMENT FOR DEMENTING ILLNESSES SUCH AS ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LTD. | 2002-10-15 | — | — | US | disclosed |
| US-6380204-B1 | ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID RECEPTOR ANTAGONIST ACTIVITY | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| US-6306864-B1 | CEREBRAL DEFICITS SUBSEQUENT TO OR RESULTING FROM CARDIAC BYPASS SURGERY AND GRAFTING, STROKE, CEREBRAL ISCHEMIA, SPINAL CORD TRAUMA, HEAD TRAUMA | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| EP-0968194-A1 | ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2000-01-05 | — | — | EP | disclosed |
| EP-0964860-A1 | ATROPISOMERS OF 3-HETEROARYL-4(3H)-QUINAZOLINONES FOR THE TREATMENT OF NEURODEGENERATIVE AND CNS-TRAUMA RELATED CONDITIONS | Pfizer Products Inc. (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998038173-A1 | ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1998038187-A1 | ATROPISOMERS OF 3-HETEROARYL-4(3H)-QUINAZOLINONES FOR THE TREATMENT OF NEURODEGENERATIVE AND CNS-TRAUMA RELATED CONDITIONS | PFIZER PRODUCTS INC. (US) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | BACE1, APP, BACE2 | PPM1B 1299/4885PTPN1 4704/4885PPP1CC 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.